MedPath

Feasibility of Endoscopic Pylorotomy in the Treatment of Refractory Gastroparesis, Pilot Study.

Not Applicable
Completed
Conditions
Gastroparesis
Interventions
Procedure: per oral pylorotomy
Registration Number
NCT02779920
Lead Sponsor
University Hospital, Limoges
Brief Summary

Gastroparesis is a common chronic condition, disabling the limited therapeutic resources justifying the exploration of new therapeutic possibilities.

By analogy to the technique of Per Oral Endoscopic Myotomy (POEM), we believe that myotomy pyloric muscle (POP = Per Oral Pyloromyotomy) endoscopically could become a treatment of choice in the refractory gastroparesis with drug treatments by attacking the pyloric obstacle often spastic that counteracts an effective gastric emptying.

Detailed Description

Experimental study, prospective, single-center, POP feasibility pilot in the treatment of refractory gastroparesis.

Patients with gastroparesis (significant prolongation of gastric emptying) unimproved by prokinetic treatment and meet all the eligibility criteria will be included after a period of reflection of two weeks minimum.

20 patients will be prospectively included 10 patients with diabetic gastroparesis, 10 patients with non-diabetic gastroparesis (post-surgical, post-Sjogren, idiopathic).

POP will be performed under general anesthesia in intubated-ventilated patients using a carbon dioxide (CO2) inflator. The published standard technique and learned by our team on the pig model will be conducted: submucosal tunnel at the anterior surface of the gastric antrum starting 3-5 cm proximal to the pylorus front section to the fiber by fiber to the muscular pyloric, then closing the inlet tunnel by hemostatic clips.

An evaluation of symptoms by the Gastroparesis Cardinal Symptom Index (ISCC) of the quality of life of the patient Assessment of upper gastrointestinal disorders-Quality Of Life (PAGI-QoL), SF-36 and gastrointestinal Quality of Life Index (GIQLI ) and gastric emptying by a scintigraphic gastric emptying will be carried out at 3 months.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Patient with refractory gastroparesis to drug treatment (post-diabetic, post-Sjogren, postsurgical or idiopathic)
  • Signed Consent
  • Affiliate or beneficiary of a French social security scheme
Exclusion Criteria
  • Contraindications to gastroesophageal gastroduodenal endoscopy,
  • Early Unable to follow protocol,
  • Contraindications to general anesthesia,
  • Can not Stop anticoagulants for the gesture,
  • Can not stop antiplatelet agents for the gesture,
  • Pregnant or lactating women,
  • Gastric resection surgery History of pyloric
  • Patients under guardianship, curatorship or safeguard justice,
  • Disorders of hemostasis against-indicating the endoscopic procedure.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Per oral pylorotomyper oral pylorotomyPatients with gastroparesis (significant prolongation of gastric emptying) not improved prokinetic and antiemetic treatments undergoing per oral pylorotomy
Primary Outcome Measures
NameTimeMethod
Number of technical success for endoscopic pylorotomy on the total number of gestures.3 months

Technical feasibility will be the feasibility of endoscopic pylorotomy gesture by the technique of the tunnel.

Secondary Outcome Measures
NameTimeMethod
Incidence of adverse events of pylorotomy3 months

analysis of adverse events during the 3 months following the pylorotomy (including perforation per-gesture, bleeding post-gesture)

Assessment of gastroparesis severity symptom using the Gastroparesis Cardinal Symptom Index (GCSI)Baseline, 1 month and 3 month

Evaluation of the severity of gastroparesis symptom using the GCSI questionnaire

Assessment of functional health and well-being from the patient's point of view (SF-36)Baseline, 1 month and 3 month

Evaluation of of functional health and well-being from the patient's point of view using SF-36 questionnaire

Assessment of Quality of Life in Upper Gastrointestinal Disorders (PAGI-QOL)Baseline, 1 month and 3 month

Evaluation of the quality of life of patient with Upper Gastrointestinal Disorders using PAGI-QOL questionnaire

Ratio between the diameter of the pyloric canal and the pyloric pressureBaseline and 3 months

Evaluation of the pyloric compliance by the Endolumenal Functional Lumen Imaging Probe (EndoFLIP) system before the procedure and at 3 months, depending on etiology.

Assessment of gastric emptying scintigraphybaseline and 3 months

Assessment of gastric emptying scintigraphy before the procedure and at 3 months by measuring the half gastric emptying time and percentage retention to 4 hours

Assessment of Quality of Life in Gastrointestinal disease (GIQLI)Baseline, 1 month and 3 month

Evaluation of quality of life of patients with gastrointestinal Disease using GIQLI questionnaire

Consumption of gastric prokinetic drugs3 months

Data collecting about domperidone, metoclopramide and erythromycin consumption.

Trial Locations

Locations (1)

CHU de LIMOGES

🇫🇷

Limoges, France

© Copyright 2025. All Rights Reserved by MedPath